

Introducing ViaLase



Tibor, Juhasz, PhD
Founder, Pres & CTO



Shawn O'Neil
Chief Executive Officer



Hadi Srass
Chief Operating Officer



Rick Lewis, MD
Chief Medical Officer



Pete England
Chief Commercial Officer



Scott Cooper
Chief Financial Officer



Brett Trauthen
SVP, Clinical & Regulatory



Ference Raksi, PhD
Chief Scientific Officer



Brendan O'Herlihy
VP, Global Ops



Kristy Miller
Head, Human Resources

Team

A leadership team with ~200 years of combined experience in **developing & commercializing femtosecond laser technology in eyecare**

Mission

Redefine the glaucoma treatment paradigm by delivering breakthrough, incision-free, image-guided, femtosecond laser treatment for glaucoma patients

The ViaLase Journey: A Legacy of Landmark Technology

From **revolutionizing vision correction** to
pioneering **incision-free glaucoma treatment**



1997 IntraLase[™]
Method




2009 LenSx[®]
LASER



2017 VIA
LASE[®]


A Surgical Procedure Without the Surgery

- + **Ultra HD gonioscopic & OCT imaging** identify landmarks with micron accuracy
- + Femtosecond laser creates **precise apertures** in the TM
- + Customized aperture number + location, enabling 360° angle access
- + **Retreatments can be performed** as needed to maintain results



Proprietary, incision-free femtosecond laser creates micron-accurate openings in the trabecular meshwork to enhance outflow and lower IOP.

First-In-Human Safety Study of FLigHT: 24-month Outcomes



Nagy Z.Z., Kranitz K., Ahmed I.I.K., De Francesco T., Mikula E. & Juhasz T., First-in-Human Safety Study of Femtosecond Laser Image Guided Trabeculotomy for Glaucoma Treatment: 24-month Outcomes, Ophthalmology Science (2023)

- ▶ **Single-channel (500 x 200μ) treatment, no washout (N = 18)**
- ▶ **No serious adverse events** related to FLigHT treatment at any timepoint
- ▶ **34.6% mean IOP reduction** at 24 mos

At 24 Months	Mean IOP	• 88% percent of eyes achieved IOP ≤ 18 mmHg
	Responder Rate	• 82% percent of eyes achieved more than 20% IOP reduction (53% of patients achieved 25% or more)

Summary



ViaLase is a med-tech startup company with the **mission to fuel the practice of incision-free interventional glaucoma**



The ViaLuxe Laser System combines **micron accurate imaging** and **femtosecond laser precision** for treatment of glaucoma



24 month first-in-human study demonstrates an **excellent safety** profile and **durable IOP reduction**



ViaLase is preparing for **controlled launch in Europe and FDA 510k Clearance**